Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/cochlear-ltd" target="_blank" data-smartkarma-citation="entities:918:1" rel="noopener">Cochlear Ltd (COH AU)</a> expects to report FY26 underlying net profit of $435–460M, an 11–17% increase on FY25, up 5–11% on a comparative (cloud adjusted) basis.</li>
<li>The Nucleus Nexa System has been launched in Europe and Asia Pacific in mid-June 2025 and will be launched in the U.S. by the end of Q1FY26.</li>
<li>The company expects strong FY26 revenue growth in developed markets from the launch of the new Nucleus Nexa implant, with overall revenue and earnings growth weighted to the second half.</li>
</ul>



Cochlear Ltd (COH AU) expects to report FY26 underlying net profit of $435–460M, an 11–17% increase on FY25, up 5–11% on a comparative (cloud adjusted) basis.
The Nucleus Nexa System has been launched in Europe and Asia Pacific in mid-June 2025 and will be launched in the U.S. by the end of Q1FY26.
The company expects strong FY26 revenue growth in developed markets from the launch of the new Nucleus Nexa implant, with overall revenue and earnings growth weighted to the second half.


Cochlear Ltd (COH AU): Earnings Recovery to Continue on Nucleus Nexa Implant Launch

Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Quantitative Analysis

<ul>
<li>We analyzed the changes in short interest of ASX Stocks as of Aug 8th (reported today). The aggregated short interest was USD25.9bn.</li>
<li>We tabulate league tables for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.</li>
<li>We highlight short interest changes in Wesfarmers, Infratil, Iluka Resources, Bigtincan, Auswide Bank.</li>
</ul>


We analyzed the changes in short interest of ASX Stocks as of Aug 8th (reported today). The aggregated short interest was USD25.9bn.
We tabulate league tables for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.
We highlight short interest changes in Wesfarmers, Infratil, Iluka Resources, Bigtincan, Auswide Bank.


ASX Short Interest Weekly (Aug 8th): Wesfarmers, Infratil, Iluka Resources, Bigtincan, Auswide Bank

<ul>
<li>We analyzed the changes in short interest of ASX Stocks as of Aug 1st (reported today). The aggregated short interest was USD24.9bn.</li>
<li>We tabulate league tables for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.</li>
<li>We highlight short interest changes in Ramelius Resources, Bluescope Steel, Boss Energy, Coles, National Australia Bank.</li>
</ul>


We analyzed the changes in short interest of ASX Stocks as of Aug 1st (reported today). The aggregated short interest was USD24.9bn.
We tabulate league tables for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.
We highlight short interest changes in Ramelius Resources, Bluescope Steel, Boss Energy, Coles, National Australia Bank.


ASX Short Interest Weekly (Aug 1st): Ramelius Resources, Bluescope Steel, Boss Energy, Coles

Financial News, Analysis and Data, FNArena

FNArena

Financial News, Analysis and Data

Online financial media company focused on Australian equities, with a global perspective

<ul><li>In today's edition: -Ask FNArena -Review All-Weather Model Portfolio -Recent Updates On Expert Views -Best Buys & Conviction Calls</li></ul>

In today's edition: -Ask FNArena -Review All-Weather Model Portfolio -Recent Updates On Expert Views -Best Buys & Conviction Calls

Rudi's View: Bega Cheese, Cettire, Harvey Norman, Sigma, SiteMinder & More

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

<ul><li>Cochlear Limited recently announced its half-year results for fiscal year 2025.</li><li>In its earnings call, the company disclosed a mixed performance across its business segments.</li><li>On the positive side, the company reported a strong 13% growth in Cochlear implant revenue and an even stronger 22% growth in Acoustics revenue, leading to an overall net sales increase of 6% in constant currency.</li></ul>

Cochlear Limited recently announced its half-year results for fiscal year 2025.In its earnings call, the company disclosed a mixed performance across its business segments.On the positive side, the company reported a strong 13% growth in Cochlear implant revenue and an even stronger 22% growth in Acoustics revenue, leading to an overall net sales increase of 6% in constant currency.

Cochlear Limited: Initiation of Coverage- Can Cutting-Edge Innovation & R&D Fuel the Next Growth Surge?

Australia

Cochlear Limited researches, develops and markets cochlear implant systems for hearing impaired individuals.  The Company's hearing implant systems include Nucleus and Baha and are sold both domestically and internationally.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Cochlear Ltd (CHEOY US)

Cochlear Ltd (COH AU): Earnings Recovery to Continue on Nucleus Nexa Implant Launch

Cochlear anticipates strong revenue growth in FY26 driven by new Nucleus Nexa System launch, with expected 11-17% increase in underlying net...

Tina Banerjee

ASX Short Interest Weekly (Aug 8th): Wesfarmers, Infratil, Iluka Resources, Bigtincan, Auswide Bank

We analyzed ASX short interest report for the past week and highlight short interest changes in Wesfarmers, Infratil, Iluka Resources, Bigtincan,...

Ke Yan, CFA, FRM

ASX Short Interest Weekly (Aug 1st): Ramelius Resources, Bluescope Steel, Boss Energy, Coles

We analyzed ASX short interest report for the past week and highlight short interest changes in Ramelius Resources, Bluescope Steel, Boss Energy,...

Ke Yan, CFA, FRM

Rudi's View: Bega Cheese, Cettire, Harvey Norman, Sigma, SiteMinder & More

In today's edition: -Ask FNArena -Review All-Weather Model Portfolio -Recent Updates On Expert Views -Best Buys & Conviction Calls

FNArena

Cochlear Limited: Initiation of Coverage- Can Cutting-Edge Innovation & R&D Fuel the Next Growth Surge?

Cochlear Limited recently announced its half-year results for fiscal year 2025. In its earnings call, the company disclosed a mixed performance...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Cochlear Ltd (COH AU): Earnings Recovery to Continue on Nucleus Nexa Implant Launch

​Cochlear anticipates strong revenue growth in FY26 driven by new Nucleus Nexa System launch, with expected 11-17% increase in underlying net...

Tina Banerjee

ASX Short Interest Weekly (Aug 8th): Wesfarmers, Infratil, Iluka Resources, Bigtincan, Auswide Bank

We analyzed ASX short interest report for the past week and highlight short interest changes in Wesfarmers, Infratil, Iluka Resources, Bigtincan,...

Ke Yan, CFA, FRM

ASX Short Interest Weekly (Aug 1st): Ramelius Resources, Bluescope Steel, Boss Energy, Coles

We analyzed ASX short interest report for the past week and highlight short interest changes in Ramelius Resources, Bluescope Steel, Boss Energy,...

Ke Yan, CFA, FRM

Rudi's View: Bega Cheese, Cettire, Harvey Norman, Sigma, SiteMinder & More

In today's edition: -Ask FNArena -Review All-Weather Model Portfolio -Recent Updates On Expert Views -Best Buys & Conviction Calls

FNArena

Cochlear Limited: Initiation of Coverage- Can Cutting-Edge Innovation & R&D Fuel the Next Growth Surge?

Cochlear Limited recently announced its half-year results for fiscal year 2025. In its earnings call, the company disclosed a mixed performance...

Baptista Research

Cochlear anticipates strong revenue growth in FY26 driven by new Nucleus Nexa System launch, with expected 11-17% increase in underlying net...